Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
+0.36%
1,096.72
+3.98
+0.36%
—1,092.741,095.951,103.321,094.72——
SIXC
Communications
SIXC
Communications
SIXC
-0.33%
611.32
-2.04
-0.33%
—613.36613.36613.36609.50——
SIXE
Energy
SIXE
Energy
SIXE
-0.45%
1,171.54
-5.25
-0.45%
—1,176.791,176.521,182.251,166.69——
SIXI
Industrials
SIXI
Industrials
SIXI
-0.45%
1,747.63
-7.91
-0.45%
—1,755.541,759.231,766.301,746.04——
SIXM
Financials
SIXM
Financials
SIXM
-0.58%
631.49
-3.66
-0.58%
—635.15635.20636.89630.09——
SIXR
Staples
SIXR
Staples
SIXR
+0.23%
849.94
+1.93
+0.23%
—848.01852.52855.78849.58——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
+0.09%
218.06
+0.20
+0.09%
—217.86217.86219.52217.86——
SIXT
Technology
SIXT
Technology
SIXT
+3.47%
3,536.03
+118.68
+3.47%
—3,417.353,452.773,536.033,450.39——
SIXU
Utilities
SIXU
Utilities
SIXU
-0.91%
905.07
-8.29
-0.91%
—913.36915.10920.43904.57——
SIXV
Health care
SIXV
Health care
SIXV
-0.86%
1,449.86
-12.52
-0.86%
—1,462.381,461.131,464.531,446.02——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0.30%
2,430.47
+7.33
+0.30%
—2,423.142,428.712,448.692,424.63——
DBV:EPA
DBV Technologies SA
€3.40
+1.31%
(+0.044) 1D
May 8, 5:35:17 PM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for DBV...
Open
€3.43
High
€3.44
Low
€3.33
Mkt. cap
904.21M
Avg. vol.
966.54K
Volume
409.12K
52-wk high
€4.50
52-wk low
€1.30
EPS
-€0.90
Shares outstanding
278.35M
No. of employees
126
News stories
From sources across the web
Profile
DBV Technologies SA is a publicly owned French biopharmaceutical firm headquartered in Bagneux, France. DBV Technologies is known for developing "Viaskin" technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood. Viaskin Peanut clinical development has received Fast Track designation from the US Food and Drug Administration. Wikipedia
About DBV Technologies SA
CEO-
Employees126
FoundedMar 29, 2002
Headquarters-
SectorBiotechnology
Websitedbv-technologies.com
Last report
Apr 30, 2026
Fiscal Period
Q1 2026
EPS / Est. (EUR)
-€0.09 / -€0.12
+22.51%beat
Revenue / Est. (EUR)
767.16K / 818.50K
-6.27%miss
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in EUR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
1.46M
2.77M
645.00K
900.00K
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
33.69M
28.62M
32.89M
33.40M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
8.88M
8.44M
12.80M
15.30M
Operating expense
42.58M
37.05M
45.70M
48.70M
Total operating expenses
42.58M
37.05M
45.70M
48.70M
Operating income
-41.11M
-34.28M
-45.05M
-47.80M
Other non operating income
-
1.00K
-1.00K
-100.00K
EBT including unusual items
-41.76M
-33.16M
-44.46M
-47.40M
EBT excluding unusual items
-41.76M
-33.16M
-44.46M
-47.40M
Income tax expense
117.00K
-
374.00K
200.00K
Effective tax rate
-0.28%
-
-0.84%
-0.42%
Other operating expenses
-
-
-
-
Net income
-41.88M
-33.16M
-44.83M
-47.60M
Net profit margin
-2,858.36%
-1,195.53%
-6,950.23%
-5,288.89%
Earnings per share
-
-
-
-
Interest and investment income
-
1.11M
597.00K
500.00K
Interest expense
-648.00K
-
-
-
Net interest expenses
-648.00K
1.11M
597.00K
500.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-40.35M
-33.49M
-44.36M
-46.90M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer